• Menu
    • Search
    • Stock Code: 00512.HK
    • About Us
      • Company Profile
      • Company History
      • Enterprise Members
    • Product Center
      • Pharmaceutical Preparations and Medical Devices
      • Bio-technology Products and Health Products
      • Specialized Pharmaceutical Raw Materials and Other Products
      • Innovative Pipeline
    • Investor Relations
      • Information Disclosure
      • Corporate Governance
      • Stock Info
      • Contact Information
    • News & Media
      • Corporate News
      • Media Reports
    • Contact Us
      • Contact Information
      • Privacy Protection
    • Language
      • EnglishEnglish
      • 繁体中文繁体中文
      • 简体中文简体中文
  • English English
    • EnglishEnglish
    • 繁体中文繁体中文
    • 简体中文简体中文
  • Stock Code: 00512.HK

News Center

  • Home
  • News Center
  • Show All
  • Corporate News
  • Media Reports
GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation  in Anti-tumor Field

GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation in Anti-tumor Field

2020-11-1 Corporate News READ MORE
Four Products of GP (HK) that Obtained Consistency Evaluation Approvals, Namely Sodium Bicarbonate Tablets, Trimetazidine Tablets, Finasteride Tablets and Captopril Tablets, Have Successfully Won the Bids in the Third Batch of National Centralized Drug Procurement

Four Products of GP (HK) that Obtained Consistency Evaluation Approvals, Namely Sodium Bicarbonate Tablets, Trimetazidine Tablets, Finasteride Tablets and Captopril Tablets, Have Successfully Won the Bids in the Third Batch of National Centralized Drug Procurement

2020-8-20 Corporate News READ MORE
GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million  With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

2020-8-10 Corporate News READ MORE
GP (HK) Enters into a Capital Subscription and Acquisition Agreement, Acquires the Third-Generation Stent Retriever Contributing to Achieve the Strategic Plan of “Treating the Heart and Brain with the Same Therapeutic Method”, Enhancing Global “Precision Diagnostics + Treatment” Planning

GP (HK) Enters into a Capital Subscription and Acquisition Agreement, Acquires the Third-Generation Stent Retriever Contributing to Achieve the Strategic Plan of “Treating the Heart and Brain with the Same Therapeutic Method”, Enhancing Global “Precision Diagnostics + Treatment” Planning

2020-7-28 Corporate News READ MORE
GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

2020-7-15 Corporate News READ MORE
GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

2020-5-31 Corporate News READ MORE
GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

2020-5-15 Corporate News READ MORE
GP (HK)’s World-wide Innovative Drug STC3141 Got Approval  for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

2020-5-7 Corporate News READ MORE
GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

2020-4-21 Corporate News READ MORE
GP (HK) Announces 2019 Annual Results

GP (HK) Announces 2019 Annual Results

2020-4-1 Corporate News READ MORE
Page 4 of 5«12345»
Contact Us

Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong

ir@grandpharm.com

www.grandpharm.com

Pages Links

Company Profile

Product Center

Investor Relations

News & Media

Stock Info

Contact Us

Privacy

Legal Statement

Recent News
  • Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

    2022-4-26

  • The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry

    2022-4-7

© 2022. Grand Pharmaceutical Group Limited All Rights Reserved.